Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bone Biologics Corp BBLG

Healthcare Biotechnology
Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The... see more

Recent & Breaking News (NDAQ:BBLG)

Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia

Business Wire April 11, 2023

Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization

Business Wire January 26, 2023

Bone Biologics CEO Issues Letter to Stockholders

Business Wire October 25, 2022

WallachBeth Capital Announces Closing of Bone Biologics $5,100,000 Underwritten Public Offering

PR Newswire October 13, 2022

Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering

Business Wire October 12, 2022

WallachBeth Capital Announces Pricing of Bone Biologics $5,100,000 Underwritten Public Offering

PR Newswire October 7, 2022

Bone Biologics Prices $5,100,000 Million Underwritten Public Offering

Business Wire October 7, 2022

Bone Biologics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

Business Wire March 23, 2022

Bone Biologics Enters into Supply Agreement with MTF Biologics for Demineralized Bone Matrix

Business Wire March 7, 2022

Bone Biologics to Present at the H.C. Wainwright BioConnect Virtual Conference

Business Wire January 5, 2022

Bone Biologics Corp. Announces Closing of Public Offering and Uplisting to Nasdaq

Business Wire October 18, 2021

WallachBeth Capital Announces Completion of Bone Biologics Corp. (NASDAQ: BBLG) $7.9 million Public Offering

PR Newswire October 15, 2021

WallachBeth Capital announces pricing of Bone Biologics Corp. (NASDAQ: BBLG) $7.9 million Public Offering and Uplisting to the NASDAQ Capital Market

PR Newswire October 13, 2021

Bone Biologics Corp. Announces Pricing of $7.9 million Public Offering; Uplisting to the Nasdaq Capital Market and Reverse Stock Split

Business Wire October 13, 2021

Bone Biologics Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation

Business Wire January 7, 2020

Milberg Phillips Grossman LLP Announces Securities Class Action Lawsuit Against Bone Biologics Corporation

PR Newswire June 20, 2019

Bone Biologics Completes $5.9 Million of Financing

Business Wire July 23, 2018

Bone Biologics Completes $500,000 of Financing

Business Wire March 29, 2018

Bone Biologics Release: New Preclinical Data For Spine Fusion Demonstrates Osteopromotive Properties

Business Wire December 20, 2017

Bone Biologics Adds Osteoporosis and Trauma Indications to its Portfolio

Business Wire August 23, 2017